Mayo Clinic 
Welcome,         Profile    Billing    Logout  
 10 Products   8 Diseases  10 Products   6 Trials   219 News 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ANX-042 / Anexon
ANX-042 Aim 1, NCT03019653: Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome

Completed
1
40
US
ANX-042, Placebo
Mayo Clinic, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
Heart Failure, Cardiorenal Disease, Renal Disfunction
09/24
09/24
LB-P8 / LISCure Biosci, Mayo Clinic
NCT06699121: A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

Not yet recruiting
2
87
US
LB-P8 low-dose, LB-P8 high-dose, Placebo
LISCure Biosciences
Primary Sclerosing Cholangitis (PSC)
03/28
02/29
autologous mesenchymal stem cells / Mayo Clinic, National Institute of Neurological Disorders and Stroke
NCT05167721: Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy

Recruiting
2
76
US
Autologous Mesenchymal Stem Cells, Placebo
Mayo Clinic
Multiple System Atrophy
12/25
12/25
NCT02315027: Mesenchymal Stem Cell Therapy in Multiple System Atrophy

Active, not recruiting
1/2
30
US
Autologous Mesenchymal Stem Cells
Mayo Clinic, Food and Drug Administration (FDA), National Institute of Neurological Disorders and Stroke (NINDS)
MSA
03/26
03/26
NCT04312113: Angiographic Delivery of AD-MSC for Ulcerative Colitis

Active, not recruiting
1
20
US
Adipose derived, autologous mesenchymal stem cells, AD-MSC
Mayo Clinic
Ulcerative Colitis
06/25
06/25
neoantigen peptide vaccine / Mayo Clinic, National Cancer Institute
PNeoVCA, NCT05269381: Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Recruiting
1/2
36
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Neoantigen Peptide Vaccine, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin
Mayo Clinic
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Cervical Carcinoma, Locally Advanced Endometrial Carcinoma, Locally Advanced Gastric Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hepatocellular Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Locally Advanced Merkel Cell Carcinoma, Locally Advanced Renal Cell Carcinoma, Locally Advanced Skin Squamous Cell Carcinoma, Locally Advanced Triple-Negative Breast Carcinoma, Locally Advanced Unresectable Breast Carcinoma, Locally Advanced Unresectable Cervical Carcinoma, Locally Advanced Unresectable Gastric Adenocarcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Locally Advanced Unresectable Renal Cell Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Merkel Cell Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Urothelial Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Skin Squamous Cell Carcinoma, Stage III Cervical Cancer AJCC v8, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Cervical Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Hepatocellular Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma, Unresectable Merkel Cell Carcinoma, Unresectable Renal Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma, Unresectable Triple-Negative Breast Carcinoma, Unresectable Urothelial Carcinoma
02/25
02/26
Akeega (abiraterone/niraparib) / J&J
MAGNITUDE, NCT03748641 / 2017-003364-12: A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

Hourglass Jul 2022 - Sep 2022 : From MAGNITUDE trial in combination with Zytiga with or without HRR gene-mutated metastatic prostate cancer
Checkmark Submitted in EU in combination with abiraterone acetate and and prednisone for mCRPC
Apr 2022 - Apr 2022: Submitted in EU in combination with abiraterone acetate and and prednisone for mCRPC
Checkmark From MAGNITUDE trial in combination with Zytiga in metastatic prostate cancer at ASCO-GU 2022
Feb 2022 - Feb 2022: From MAGNITUDE trial in combination with Zytiga in metastatic prostate cancer at ASCO-GU 2022
Active, not recruiting
3
765
Europe, Canada, US, RoW
Niraparib, JNJ-64091742, Abiraterone Acetate, Prednisone, Placebo, New Formulation of Niraparib and Abiraterone Acetate (AA)
Janssen Research & Development, LLC
Castration-Resistant Prostatic Cancer
10/21
02/27
STAMPEDE2, NCT06320067: A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

Recruiting
3
8000
Europe
Stereotactic Ablative Body Radiotherapy (SABR), Stereotactic body radiotherapy (SBRT), 177Lu-PSMA-617, Lutetium (177Lu) Vipivotide Tetraxetan, AAA617, Pluvicto, Niraparib and Abiraterone Acetate Dual Action Tablet DAT, Nira-AA, CJNJ-67652000-ZZZ, Abiraterone Acetate, Zytiga, Apalutamide, Erleada, JNJ-56021927, Androgen Deprivation Therapy (ADT), Androgen Receptor Signalling Inhibitor (ARSI), Local Radiotherapy, Prednisolone, Docetaxel
University College, London, Cancer Research UK, Novartis, Janssen Pharmaceutica NV
Prostate Cancer Metastatic
04/31
03/34
ProBio, NCT03903835 / 2018-002350-78: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

Recruiting
3
750
Europe
Enzalutamide Oral Capsule, Xtandi, Abiraterone Oral Tablet, Zytiga, Carboplatin, Cabazitaxel 60 mg Solution for Injection, Docetaxel Injectable Solution, Radium Chloride Ra-223, Xofigo, Niraparib plus Abiraterone acetate plus Prednisone, Akeega, Capivasertib plus Docetaxel, Apalutamide, Erleada, Darolutamide, Nubeqa
Karolinska Institutet, The Swedish Research Council, Kom Op Tegen Kanker, Janssen Pharmaceutica N.V., Belgium, AstraZeneca, Cancerfonden
Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
12/26
12/26
NCT05689021: CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

Recruiting
2
30
US
Abiraterone Acetate/Niraparib, Abiraterone Acetate and Niraparib Tosylate Monohydrate, Abiraterone Acetate/Niraparib Tosylate Monohydrate, Akeega, CJNJ-67652000, Niraparib and Abiraterone Acetate, Niraparib Tosylate Monohydrate and Abiraterone Acetate, Niraparib Tosylate Monohydrate/Abiraterone Acetate, Niraparib/Abiraterone Acetate, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone
Mayo Clinic
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC V8
09/25
09/25
HARMONY, NCT06392841: Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations

Recruiting
2
64
US
Androgen Deprivation Therapy (ADT), Niraparib/Abiraterone Acetate DAT, Akeega, Abiraterone Acetate, Zytiga, Prednisone, Rayos, Deltasone, Prednisone Intensol, Docetaxel, Docefrez, Taxotere
Qian Qin, UT Southwestern Comprehensive Cancer Center, Janssen, LP
Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CHEK2 Gene Mutation, FANCA Gene Mutation, PALB2 Gene Mutation, RAD51B Gene Mutation, RAD54L Gene Mutation
04/27
04/28
LUNAAR, NCT06329830: 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer

Withdrawn
1/2
30
US
177Lu-PSMA-617, Pluvicto, Niraparib abiraterone acetate, Akeega, Prednisone, Rayos, Prednisone Intensol, Deltasone
Baptist Health South Florida, Janssen Scientific Affairs, LLC
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
10/26
10/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ANX-042 / Anexon
ANX-042 Aim 1, NCT03019653: Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome

Completed
1
40
US
ANX-042, Placebo
Mayo Clinic, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
Heart Failure, Cardiorenal Disease, Renal Disfunction
09/24
09/24
LB-P8 / LISCure Biosci, Mayo Clinic
NCT06699121: A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

Not yet recruiting
2
87
US
LB-P8 low-dose, LB-P8 high-dose, Placebo
LISCure Biosciences
Primary Sclerosing Cholangitis (PSC)
03/28
02/29
autologous mesenchymal stem cells / Mayo Clinic, National Institute of Neurological Disorders and Stroke
NCT05167721: Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy

Recruiting
2
76
US
Autologous Mesenchymal Stem Cells, Placebo
Mayo Clinic
Multiple System Atrophy
12/25
12/25
NCT02315027: Mesenchymal Stem Cell Therapy in Multiple System Atrophy

Active, not recruiting
1/2
30
US
Autologous Mesenchymal Stem Cells
Mayo Clinic, Food and Drug Administration (FDA), National Institute of Neurological Disorders and Stroke (NINDS)
MSA
03/26
03/26
NCT04312113: Angiographic Delivery of AD-MSC for Ulcerative Colitis

Active, not recruiting
1
20
US
Adipose derived, autologous mesenchymal stem cells, AD-MSC
Mayo Clinic
Ulcerative Colitis
06/25
06/25
neoantigen peptide vaccine / Mayo Clinic, National Cancer Institute
PNeoVCA, NCT05269381: Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Recruiting
1/2
36
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Neoantigen Peptide Vaccine, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin
Mayo Clinic
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Cervical Carcinoma, Locally Advanced Endometrial Carcinoma, Locally Advanced Gastric Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hepatocellular Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Locally Advanced Merkel Cell Carcinoma, Locally Advanced Renal Cell Carcinoma, Locally Advanced Skin Squamous Cell Carcinoma, Locally Advanced Triple-Negative Breast Carcinoma, Locally Advanced Unresectable Breast Carcinoma, Locally Advanced Unresectable Cervical Carcinoma, Locally Advanced Unresectable Gastric Adenocarcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Locally Advanced Unresectable Renal Cell Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Merkel Cell Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Urothelial Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Skin Squamous Cell Carcinoma, Stage III Cervical Cancer AJCC v8, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Cervical Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Hepatocellular Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma, Unresectable Merkel Cell Carcinoma, Unresectable Renal Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma, Unresectable Triple-Negative Breast Carcinoma, Unresectable Urothelial Carcinoma
02/25
02/26
Akeega (abiraterone/niraparib) / J&J
MAGNITUDE, NCT03748641 / 2017-003364-12: A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

Hourglass Jul 2022 - Sep 2022 : From MAGNITUDE trial in combination with Zytiga with or without HRR gene-mutated metastatic prostate cancer
Checkmark Submitted in EU in combination with abiraterone acetate and and prednisone for mCRPC
Apr 2022 - Apr 2022: Submitted in EU in combination with abiraterone acetate and and prednisone for mCRPC
Checkmark From MAGNITUDE trial in combination with Zytiga in metastatic prostate cancer at ASCO-GU 2022
Feb 2022 - Feb 2022: From MAGNITUDE trial in combination with Zytiga in metastatic prostate cancer at ASCO-GU 2022
Active, not recruiting
3
765
Europe, Canada, US, RoW
Niraparib, JNJ-64091742, Abiraterone Acetate, Prednisone, Placebo, New Formulation of Niraparib and Abiraterone Acetate (AA)
Janssen Research & Development, LLC
Castration-Resistant Prostatic Cancer
10/21
02/27
STAMPEDE2, NCT06320067: A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

Recruiting
3
8000
Europe
Stereotactic Ablative Body Radiotherapy (SABR), Stereotactic body radiotherapy (SBRT), 177Lu-PSMA-617, Lutetium (177Lu) Vipivotide Tetraxetan, AAA617, Pluvicto, Niraparib and Abiraterone Acetate Dual Action Tablet DAT, Nira-AA, CJNJ-67652000-ZZZ, Abiraterone Acetate, Zytiga, Apalutamide, Erleada, JNJ-56021927, Androgen Deprivation Therapy (ADT), Androgen Receptor Signalling Inhibitor (ARSI), Local Radiotherapy, Prednisolone, Docetaxel
University College, London, Cancer Research UK, Novartis, Janssen Pharmaceutica NV
Prostate Cancer Metastatic
04/31
03/34
ProBio, NCT03903835 / 2018-002350-78: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

Recruiting
3
750
Europe
Enzalutamide Oral Capsule, Xtandi, Abiraterone Oral Tablet, Zytiga, Carboplatin, Cabazitaxel 60 mg Solution for Injection, Docetaxel Injectable Solution, Radium Chloride Ra-223, Xofigo, Niraparib plus Abiraterone acetate plus Prednisone, Akeega, Capivasertib plus Docetaxel, Apalutamide, Erleada, Darolutamide, Nubeqa
Karolinska Institutet, The Swedish Research Council, Kom Op Tegen Kanker, Janssen Pharmaceutica N.V., Belgium, AstraZeneca, Cancerfonden
Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
12/26
12/26
NCT05689021: CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

Recruiting
2
30
US
Abiraterone Acetate/Niraparib, Abiraterone Acetate and Niraparib Tosylate Monohydrate, Abiraterone Acetate/Niraparib Tosylate Monohydrate, Akeega, CJNJ-67652000, Niraparib and Abiraterone Acetate, Niraparib Tosylate Monohydrate and Abiraterone Acetate, Niraparib Tosylate Monohydrate/Abiraterone Acetate, Niraparib/Abiraterone Acetate, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone
Mayo Clinic
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC V8
09/25
09/25
HARMONY, NCT06392841: Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations

Recruiting
2
64
US
Androgen Deprivation Therapy (ADT), Niraparib/Abiraterone Acetate DAT, Akeega, Abiraterone Acetate, Zytiga, Prednisone, Rayos, Deltasone, Prednisone Intensol, Docetaxel, Docefrez, Taxotere
Qian Qin, UT Southwestern Comprehensive Cancer Center, Janssen, LP
Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CHEK2 Gene Mutation, FANCA Gene Mutation, PALB2 Gene Mutation, RAD51B Gene Mutation, RAD54L Gene Mutation
04/27
04/28
LUNAAR, NCT06329830: 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer

Withdrawn
1/2
30
US
177Lu-PSMA-617, Pluvicto, Niraparib abiraterone acetate, Akeega, Prednisone, Rayos, Prednisone Intensol, Deltasone
Baptist Health South Florida, Janssen Scientific Affairs, LLC
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
10/26
10/28

Download Options